As an experimental model of acquired Creutzfeldt-Jakob disease (CJD), we performed transmission studies of sporadic CJD using knock-in mice expressing human prion protein (PrP). 
INTRODUCTION
Prion diseases are lethal transmissible neurodegenerative diseases caused by an abnormal isoform of prion protein (PrP Sc ), a component of a proteinaceous infectious particle named prion, which is converted from the normal cellular isoform (PrP C ). 1 The conformational conversion of PrP C is believed to occur: (1) spontaneously in sporadic Creutzfeldt-Jakob disease (sCJD) and variably protease-sensitive prionopathy, (2) as a consequence of a pathogenic PRNP mutation in genetic CJD, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia, (3) through an acquired prion infection in iatrogenic CJD, kuru, and variant CJD. Proven sources of iatrogenic CJD transmission include dura mater grafts, growth and gonadotrophic hormone parenteral administration, neurosurgical instruments, corneal grafts, and stereotactic intracranial electrodes, 2 while kuru, the other acquired form of prion disease related to sCJD, likely originated from the transmission of prions through ritual cannibalism. 3 As an experimental model of acquired CJD, transmission studies using knock-in mice expressing human PrP C have been extensively pursued over the last decade. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These animal models have successfully clarified the pathogenesis of acquired CJD, particularly the relationship between PRNP polymorphism and disease susceptibility or disease phenotype. 16 One of the most important findings in these animal models is the neuropathological and biochemical characteristics of acquired CJD that would help to distinguish acquired CJD cases from sporadic cases. In this review, we summarize recent advances provided by experimental transmission studies of sCJD prions with implication for the diagnostic approach aimed at identifying acquired CJD cases.
PHENOTYPIC HETEROGENEITY OF ANIMAL MODELS OF ACQUIRED CJD
To model acquired CJD, a range of sCJD isolates have been inoculated into knock-in mice expressing human PrP C with each one of the three PRNP codon 129 genotypes (methionine homozygosity, M/M; valine homozygosity, V/V; or methionine/valine heterozygosity, M/V). 
IDENTIFICATION OF ACQUIRED CJD AMONG SPORADIC CASES
Assuming that the 129M/M genotype, type i PrP Sc , and kuru plaques represent reliable markers of acquired CJD, we searched the literature for CJD cases with these distinctive features and found two of them, previously reported as sCJD, in a neurosurgeon and in a patient with a medical history of neurosurgery without dural grafting. 34 In transmission experiments, these two atypical CJD cases showed the same properties as those of plaque-type dCJD ( Table 2 ). Most significantly, at variance with most sCJD prions in which the codon 129 genotypic homology between inoculated animals and the inoculum strongly favors disease susceptibility, 16 these two 129M/M cases were transmitted most efficiently into 129 V/V mice, despite the mismatched genotype. Moreover, like the sCJD strain V2 they induced the formation of PrP Sc type 2 (V2 PrP Sc ) in the brain of these mice. Based on these findings, we concluded that the two atypical CJD cases, likewise plaque-type dCJD, actually represent acquired cases of CJD caused by the sCJD strain V2. 34 In summary, the two atypical CJD cases and plaque-type dCJD cases showed the same transmission properties as those of the parental sCJD strain V2, with the highest susceptibility in 129 V/V mice and generation of V2 PrP Sc , thus representing an example of the so-called "traceback phenomenon".
6,35

CRITERIA TO IDENTIFY ACQUIRED CJD
Based on the findings described above, we have proposed neuropathological and biochemical criteria to identify acquired CJD cases caused by transmission of the sCJD strain V2 to the 129M/M individuals, denoted as acquired CJD-MMiK (129M/M genotype, type i PrP Sc , and kuru plaques) (Fig. 1A) . 34 The distinction between type i PrP Sc and type 1 PrP Sc is rather difficult with conventional western blot analysis due to subtle differences in the electrophoretic mobility of the two fragments. This is presumably the reason why PrP Sc type i has not been reported in acquired prion disease patients other than plaque-type dCJD. For their precise distinction, stringent conditions for protease treatment and high resolution gel electrophoresis systems such as Bis-tris long gels or 10-20% gradient Tris-glycine long gels are needed. 20 Alternatively, an analysis of the electrophoretic patterns of the carboxyl terminal PrP Sc fragments using carboxyl terminus-directing antibodies is also quite useful to distinguish PrP Sc type i from PrP Sc type 1. 34 Furthermore, the characteristic transmission properties also provide a sound basis for the differential diagnosis of the acquired CJD-MMiK as described above (Fig. 1B) . To determine the transmission properties of a given CJD inoculum, the follicular dendritic cell assay following intraperitoneal inoculation into PrP-humanized knock-in mice 4 can be a time-saving alternative to the standard intracerebral transmission that requires long incubation period until disease onset. In addition, in vitro conversion assays using PrP C carrying each of the codon 129 genotype as substrate, e.g., protein misfolding cyclic amplification, 36,37 may also be useful to determine the seeded conversion activity and resulting PrP Sc type.
Besides the neuropathological, biochemical, and transmission properties, clinical features of the acquired CJD-MMiK can also be distinctive as revealed by comparative studies of plaque-type and non-plaque-type dCJD patients. 21, 22 The distinctive clinical features of the acquired CJD-MMiK include gait disturbance as an initial symptom, slow progression of disease, and absence or late occurrence of periodic sharp-wave complexes on electroencephalogram.
CONCLUDING REMARKS
Animal models of acquired CJD have contributed greatly to the evaluation of the PRNP genotypic effects on disease susceptibility or disease phenotype. The data obtained from animal experiments, combined with the phenotypic characterization of CJD patients have prompted the proposal of diagnostic criteria to identify acquired CJD among presumed sporadic cases as summarized in this review. However, this diagnostic approach is applicable only to a small portion of acquired CJD cases, i.e., the 129M/M individuals infected with the sCJD strain V2.
Unfortunately, the other acquired CJD cases, i.e., the other combinations between host PRNP genotype and prion strain, cannot be distinguished from sCJD by neuropathological and biochemical analyses, as revealed by the animal models. Nevertheless, further continuous surveillance of acquired CJD cases using the proposed diagnostic approach and the identification of transmission routes in such cases may help to reduce the risk of iatrogenic CJD transmission in the future.
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